Neurocrine Biosciences Stock 10-Day Winning Spree: Stock Climbs 19%
Neurocrine Biosciences (NBIX) – a pharmaceutical company developing treatments for neurological disorders – hit a 10-day winning streak, with cumulative gains over this period amounting to 19%. The company’s market cap has surged by about $2.5 Bil over the last 10 days and currently stands at $15 Bil.
Is this an opportunity or a trap? There is not much to fear in NBIX stock given its overall Very Strong operating performance and financial condition. This isn’t appropriately reflected in the stock’s Moderate valuation which is why we think it is Attractive (For details, see Buy or Sell NBIX).
But here is the interesting part. You are reading about this 19% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Is the Arista Rally Over? The Path to $111
- Get Paid 12% To Buy AVGO At A 30% Discount – Here’s How
- Is United Rentals Stock Utilizing Systematic Share Retirement for Long-Term Alpha?
- Micron Stock Surged 9x But History Suggests Caution.
- Can LRCX Stock Live Up To Its Multiple?
- Does Exxon Mobil Stock Still Have Room to Run?
The following table summarizes the return for NBIX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | NBIX | S&P 500 |
|---|---|---|
| 1D | 1.8% | 0.8% |
| 10D (Current Streak) | 19.2% | 3.3% |
| 1M (21D) | 15.7% | 8.4% |
| 3M (63D) | 7.8% | 6.7% |
| YTD 2026 | 7.3% | 8.1% |
| 2025 | 3.9% | 16.4% |
| 2024 | 3.6% | 23.3% |
| 2023 | 10.3% | 24.2% |
However, big gains can follow sharp reversals – but how has NBIX behaved after prior drops? See NBIX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 39 S&P constituents with 3 days or more of consecutive gains and 66 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 13 | 28 |
| 4D | 14 | 16 |
| 5D | 8 | 6 |
| 6D | 3 | 15 |
| 7D or more | 1 | 1 |
| Total >=3 D | 39 | 66 |
Key Financials for Neurocrine Biosciences (NBIX)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $2.4 Bil | $2.9 Bil |
| Operating Income | $583.0 Mil | $636.5 Mil |
| Net Income | $341.3 Mil | $478.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $805.5 Mil | $814.5 Mil |
| Operating Income | $227.9 Mil | $186.0 Mil |
| Net Income | $153.7 Mil | $197.9 Mil |
While NBIX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.